成長ホルモン欠乏症の世界市場

成長ホルモン欠乏症の世界市場は2030年までに52億米ドルに達する

2024年に44億米ドルと推定される成長ホルモン欠乏症の世界市場は、2024年から2030年にかけてCAGR 3.1％で成長し、2030年には52億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである治療薬は、CAGR 2.1%を記録し、分析期間終了時には19億米ドルに達すると予想されます。遺伝子組換えヒト成長ホルモン治療分野の成長率は、分析期間中CAGR 4.0%と推定されます。

米国市場は12億米ドル、中国はCAGR5.7%で成長すると予測

米国の成長ホルモン欠乏症市場は2024年に12億米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2024-2030年のCAGRを5.7%として、2030年までに10億米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ1.3％と2.3％と予測されています。欧州では、ドイツがCAGR 1.7%で成長すると予測されています。

世界の成長ホルモン欠乏症市場- 主要動向と促進要因のまとめ

成長ホルモン欠乏症が小児医療と成人医療で注目されるようになった理由とは？

まれではあるが重要な内分泌疾患である成長ホルモン欠乏症（GHD）は、小児および成人の集団における診断意識の高まりと治療介入の拡大により、世界の注目が高まっています。GHDは、下垂体から十分な量の成長ホルモンが分泌されない場合に発症し、小児では成長の遅れ、成人では代謝の不均衡につながります。従来は小児の疾患と考えられてきたが、下垂体腫瘍、外傷、または加齢に関連する成人発症GHDは現在、より頻繁に診断されるようになっており、より幅広い患者層と持続的な治療需要に寄与しています。

世界的に、GHDの発生率は比較的低いままであるが、この疾患の複雑な症状と長期にわたる合併症により、早期発見と早期介入に臨床的焦点が当てられています。小児では、GHDを未治療のままにしておくと、低身長、思春期の遅れ、骨の開発不良が生じる。成人では、筋肉量の減少、疲労、脂肪蓄積の増加、生活の質の低下などの症状が現れます。これらの症状は、ホルモンレベルのスクリーニングや画像診断の進歩と相まって、地域全体で同定率の改善につながりました。ヘルスケアへのアクセスの向上と内分泌学会による啓発キャンペーンは、特に新興市場において診断の足跡をさらに拡大しています。

患者のニーズと技術革新に対応して、治療方法はどのように進化しているか？

GHDの標準治療は、遺伝子組換えヒト成長ホルモン（rhGH）を毎日皮下注射するもので、ホルモンレベルの回復と臨床転帰の改善に有効であることが証明されています。しかし、頻繁な注射の負担と服薬アドヒアランスの課題（特に小児）により、薬剤の製剤とデリバリー方法に大きな技術革新がもたらされました。ソーマパシタンやロナペグソマトローピンなどの長時間作用型成長ホルモンアナログが現在市場に参入しており、週1回あるいはそれ以下の頻度で投与する選択肢を提供することで、患者の利便性とコンプライアンスを向上させています。

バイオ製薬会社はまた、注射針を使わない送達技術、徐放性マイクロスフェア・システム、投与を簡略化し注射に伴う不快感を軽減する自動注射器ペンにも投資しています。これと並行して、バイオマーカーや遺伝子プロファイリングを活用した個別化治療のアプローチも検討されており、投与戦略を調整し、治療反応をより正確にモニタリングできるようになっています。遠隔モニタリング、患者リマインダー、モバイルベースのアドヒアランス追跡を可能にするデジタルヘルスプラットフォームは、特に遠隔医療インフラが成熟している先進地域では、GHD管理プロトコールとの統合が進んでいます。

このマーケットで成長のカタリストとして台頭しているセグメントと地域は？

小児部門は、早期スクリーニングプロトコルと子供の発育期を通じた一貫した治療需要により、GHD治療市場を独占し続けています。しかし、成人のGHD診断は、心臓血管の健康、精神的幸福、代謝調節への影響に対する理解の高まりに後押しされ、牽引力を増しています。内分泌病専門医は現在、頭蓋照射、下垂体手術、外傷性脳損傷を受けた成人のスクリーニングをより積極的に行っており、これらは従来の診断枠組みでは見過ごされていた集団です。

地域別では、北米が依然として最大の市場であり、強力なヘルスケア・インフラ、ホルモン療法に対する幅広い保険適用、活発な臨床研究に支えられています。欧州は、長時間作用型治療薬の採用が増加し、有利な償還政策がとられていることから、その後に続いています。アジア太平洋地域は、中間層の医療アクセスの拡大、小児医療に対する意識の高まり、中国、インド、韓国などの内分泌診断能力の向上により、高成長地域として浮上しています。さらに、これらの地域におけるバイオシミラーの規制当局による承認は、治療コストの削減と患者アクセスの拡大に役立っています。

成長ホルモン欠乏症市場の成長はいくつかの要因によってもたらされる...

成長ホルモン欠乏症市場の成長は、治療法の革新、エンドユーザーの拡大、ヘルスケアシステムの進歩に根ざしたいくつかの要因によって牽引されています。技術革新、特に長時間作用型成長ホルモンアナログと高度なデリバリーデバイスの発売は、アドヒアランスの改善、投与負担の軽減、患者満足度の向上により、治療パラダイムを再構築しています。バイオシミラーrhGH製剤の開発も、手頃な価格の製品を増やし、コストに敏感な地域への市場浸透を拡大することで、市場開拓に寄与しています。

最終用途の面では、成人の診断基盤の拡大、学校や診療所における小児科検診の増加、内分泌の健康に対する意識の高まりが、年齢層を超えて持続的な需要を牽引しています。内分泌専門クリニックの拡大とデジタルヘルスモニタリングツールの統合は、長期治療の開始と管理を容易にしています。さらに、特に先進国市場における有利な償還制度と、希少内分泌疾患に特化した専門バイオファーマの存在感の高まりが、製品のイノベーションとアクセスを加速させています。これらの力学が相まって、成長ホルモン欠乏症市場は、患者中心の、テクノロジーを駆使した治療提供の新時代へと突き進んでいます。

セグメント

治療タイプ（治療薬、遺伝子組換えヒト成長ホルモン、ヒト下垂体腺抽出物、手術）、適応疾患（小児成長ホルモン欠乏症、特発性低身長症、妊娠低年齢児、ターナー症候群、成人成長ホルモン欠乏症、その他の適応疾患）、投与ルート（皮下投与ルート、筋肉内投与ルート、静脈内投与ルート）、流通チャネル（病院薬局流通チャネル、小売薬局流通チャネル、オンライン薬局流通チャネル）

調査対象企業の例（全34件）

• Anhui Anke Biotechnology（Group）Co., Ltd.
• Ascendis Pharma A/S
• Besins Healthcare
• Biopartners GmbH
• Braasch Biotech LLC
• Eli Lilly and Company
• EMD Serono
• Ferring Pharmaceuticals
• Genentech, Inc.
• I-Mab Biopharma Co. Ltd.
• Ipsen S.A.
• Lifetech Labs
• Merck KGaA
• Novartis AG
• Novo Nordisk A/S
• OPKO Health, Inc.
• Pfizer Inc.
• Sandoz International GmbH
• Versartis, Inc.
• Zhongshan Sinobioway Hygene Biomedicine Co., Ltd.

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、人為的な売上原価の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

Global Industry Analystsは、世界の主要なチーフ・エコノミスト（1万4,949人）、シンクタンク（62団体）、貿易・産業団体（171団体）の専門家の意見に熱心に従いながら、エコシステムへの影響を評価し、新たな市場の現実に対処しています。あらゆる主要国の専門家やエコノミストが、関税とそれが自国に与える影響についての意見を追跡調査しています。

Global Industry Analystsは、この混乱が今後2-3ヶ月で収束し、新しい世界秩序がより明確に確立されると予想しています。Global Industry Analystsは、これらの開発をリアルタイムで追跡しています。

2025年4月：交渉フェーズ

4月のリリースでは、世界市場全体に対する関税の影響を取り上げ、地域別の市場調整について紹介します。当社の予測は、過去のデータと進化する市場影響要因に基づいています。

2025年7月：最終関税リセット

無料アップデート弊社のお客様には、各国間で最終リセットが発表された後、7月に無料アップデート版をお届けします。最終アップデート版には、明確に定義された関税影響分析が組み込まれています。

相互および二国間貿易と関税の影響分析：

アメリカ <>中国<>メキシコ <>カナダ <>EU <>日本<>インド <>その他176カ国

業界をリードするエコノミスト：Global Industry Analystsの知識ベースは、国家、シンクタンク、貿易・産業団体、大企業、そして世界の計量経済状況におけるこの前例のないパラダイムシフトの影響を共有する領域の専門家など、最も影響力のあるチーフエコノミストの厳選されたグループを含む1万4,949人のエコノミストを追跡しています。我々の16,491以上のレポートのほとんどは、マイルストーンに基づくこの2段階のリリーススケジュールを取り入れています。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Growth Hormone Deficiency Market to Reach US$5.2 Billion by 2030

The global market for Growth Hormone Deficiency estimated at US$4.4 Billion in the year 2024, is expected to reach US$5.2 Billion by 2030, growing at a CAGR of 3.1% over the analysis period 2024-2030. Therapeutic Treatment, one of the segments analyzed in the report, is expected to record a 2.1% CAGR and reach US$1.9 Billion by the end of the analysis period. Growth in the Recombinant Human Growth Hormone Treatment segment is estimated at 4.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.2 Billion While China is Forecast to Grow at 5.7% CAGR

The Growth Hormone Deficiency market in the U.S. is estimated at US$1.2 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.0 Billion by the year 2030 trailing a CAGR of 5.7% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.3% and 2.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.7% CAGR.

Global Growth Hormone Deficiency Market - Key Trends & Drivers Summarized

Why Is Growth Hormone Deficiency Becoming a More Prominent Concern in Pediatric and Adult Health?

Growth Hormone Deficiency (GHD), a rare but significant endocrine disorder, is receiving increased global attention due to rising diagnostic awareness and expanding therapeutic interventions across pediatric and adult populations. GHD occurs when the pituitary gland fails to produce sufficient levels of growth hormone, leading to delayed growth in children and metabolic imbalances in adults. While traditionally viewed as a pediatric condition, adult-onset GHD-linked to pituitary tumors, trauma, or aging-is now being more frequently diagnosed, contributing to broader patient demographics and sustained treatment demand.

Globally, the incidence of GHD remains relatively low, but the condition’s complex presentation and long-term complications have driven clinical focus on early detection and intervention. In children, untreated GHD leads to short stature, delayed puberty, and poor bone development. Among adults, symptoms include reduced muscle mass, fatigue, increased fat accumulation, and diminished quality of life. These manifestations, coupled with advancements in hormone level screening and imaging diagnostics, have led to improved identification rates across geographies. Increased healthcare access and awareness campaigns by endocrine associations are further expanding the diagnostic footprint, particularly in emerging markets.

How Are Treatment Modalities Evolving in Response to Patient Needs and Innovation?

The standard treatment for GHD involves daily subcutaneous injections of recombinant human growth hormone (rhGH), a therapy that has proven to be effective in restoring hormone levels and improving clinical outcomes. However, the burden of frequent injections and adherence challenges-especially among children-have led to significant innovation in drug formulation and delivery methods. Long-acting growth hormone analogs, such as somapacitan and lonapegsomatropin, are now entering the market, offering weekly or even less frequent dosing options, thereby improving patient convenience and compliance.

Biopharmaceutical companies are also investing in needle-free delivery technologies, sustained-release microsphere systems, and autoinjector pens that simplify administration and reduce injection-associated discomfort. In parallel, personalized treatment approaches leveraging biomarkers and genetic profiling are being explored to tailor dosing strategies and monitor therapeutic response with greater precision. Digital health platforms that enable remote monitoring, patient reminders, and mobile-based adherence tracking are increasingly being integrated with GHD management protocols, especially in developed regions where telehealth infrastructure is mature.

Which Segments and Regions Are Emerging as Growth Catalysts in This Market?

The pediatric segment continues to dominate the GHD treatment market due to early screening protocols and consistent therapy demand throughout a child’s developmental years. However, adult GHD diagnosis is gaining traction, fueled by increased understanding of its impact on cardiovascular health, mental well-being, and metabolic regulation. Endocrinologists are now more proactive in screening adults who have undergone cranial irradiation, pituitary surgeries, or experienced traumatic brain injuries-populations previously overlooked in traditional diagnostic frameworks.

From a regional perspective, North America remains the largest market, supported by strong healthcare infrastructure, broad insurance coverage for hormonal therapies, and active clinical research. Europe follows closely, with increasing adoption of long-acting therapies and favorable reimbursement policies. Asia-Pacific is emerging as a high-growth region due to expanding middle-class healthcare access, rising pediatric care awareness, and improved endocrine diagnostic capabilities in countries such as China, India, and South Korea. Additionally, regulatory approvals of biosimilars in these regions are helping to lower treatment costs and expand patient access.

The Growth in the Growth Hormone Deficiency Market Is Driven by Several Factors…

The growth in the growth hormone deficiency market is driven by several factors rooted in therapeutic innovation, end-user expansion, and healthcare system advancements. Technological innovations-particularly the launch of long-acting growth hormone analogs and advanced delivery devices-are reshaping treatment paradigms by improving adherence, reducing administration burden, and enhancing patient satisfaction. The development of biosimilar rhGH products is also contributing to market growth by increasing affordability and broadening market penetration in cost-sensitive regions.

On the end-use front, the widening diagnostic base among adults, increased pediatric screening in schools and clinics, and rising awareness about endocrine health are driving sustained demand across age groups. The expansion of specialty endocrinology clinics, coupled with the integration of digital health monitoring tools, is making it easier to initiate and manage long-term therapy. Furthermore, favorable reimbursement structures, particularly in developed markets, and the increasing presence of specialty biopharma players focused on rare endocrine disorders are accelerating product innovation and access. Collectively, these dynamics are propelling the growth hormone deficiency market into a new era of patient-centric, technology-enabled treatment delivery.

SCOPE OF STUDY:

The report analyzes the Growth Hormone Deficiency market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Treatment Type (Therapeutic, Recombinant Human Growth Hormone, Human Pituitary Gland Extracts, Surgery); Disease Indication (Pediatric Growth Hormone Deficiency, Idiopathic Short Stature, Small for Gestational Age, Turner Syndrome, Adult Growth Hormone Deficiency, Other Disease Indications); Administration Route (Subcutaneous Administration Route, Intramuscular Administration Route, Intravenous Administration Route); Distribution Channel (Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

• Anhui Anke Biotechnology (Group) Co., Ltd.
• Ascendis Pharma A/S
• Besins Healthcare
• Biopartners GmbH
• Braasch Biotech LLC
• Eli Lilly and Company
• EMD Serono
• Ferring Pharmaceuticals
• Genentech, Inc.
• I-Mab Biopharma Co. Ltd.
• Ipsen S.A.
• Lifetech Labs
• Merck KGaA
• Novartis AG
• Novo Nordisk A/S
• OPKO Health, Inc.
• Pfizer Inc.
• Sandoz International GmbH
• Versartis, Inc.
• Zhongshan Sinobioway Hygene Biomedicine Co., Ltd.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Impact of Covid-19 and a Looming Global Recession
  • Growth Hormone Deficiency - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Awareness and Diagnosis Rates Propel Demand for Growth Hormone Deficiency Treatments
  • Expansion of Pediatric Endocrinology Services Strengthens Market Penetration in Early Diagnosis
  • Technological Advancements in Injection Devices Improve Patient Compliance and Therapy Outcomes
  • Regulatory Approvals for Long-Acting Growth Hormone Formulations Drive Adoption in Pediatric and Adult Segments
  • Integration of Digital Health Monitoring Tools Enhances Treatment Adherence and Patient Tracking
  • Increased Availability of Recombinant Human Growth Hormone (rhGH) Expands Access in Emerging Markets
  • Growing Research in Genetic Causes of GHD Throws the Spotlight on Personalized Treatment Approaches
  • Insurance Coverage Expansion in Developed Markets Sustains Growth in Prescription Volumes
  • Rising Incidence of Pituitary Disorders and Genetic Syndromes Spurs GHD Therapy Demand
  • Development of Biosimilar Growth Hormones Enhances Affordability and Market Competition
  • Improved Awareness Among Pediatricians and General Practitioners Strengthens Early Detection Rates
  • Evolving Clinical Guidelines and Treatment Protocols Standardize Diagnosis and Therapy Practices
  • Growth in Tele-endocrinology Services Expands Reach to Underserved and Rural Patient Populations
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Growth Hormone Deficiency Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Growth Hormone Deficiency by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Growth Hormone Deficiency by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Growth Hormone Deficiency by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Therapeutic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Therapeutic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Therapeutic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Recombinant Human Growth Hormone by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Recombinant Human Growth Hormone by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Recombinant Human Growth Hormone by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Human Pituitary Gland Extracts by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Human Pituitary Gland Extracts by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Human Pituitary Gland Extracts by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Surgery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Surgery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Surgery by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Other Disease Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Other Disease Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Other Disease Indications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Pediatric Growth Hormone Deficiency by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Pediatric Growth Hormone Deficiency by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Pediatric Growth Hormone Deficiency by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Idiopathic Short Stature by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Idiopathic Short Stature by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Idiopathic Short Stature by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Small for Gestational Age by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Small for Gestational Age by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Small for Gestational Age by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Turner Syndrome by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Turner Syndrome by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 31: World 15-Year Perspective for Turner Syndrome by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Adult Growth Hormone Deficiency by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Adult Growth Hormone Deficiency by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 34: World 15-Year Perspective for Adult Growth Hormone Deficiency by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Subcutaneous Administration Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Subcutaneous Administration Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 37: World 15-Year Perspective for Subcutaneous Administration Route by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 38: World Recent Past, Current & Future Analysis for Intramuscular Administration Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 39: World Historic Review for Intramuscular Administration Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 40: World 15-Year Perspective for Intramuscular Administration Route by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 41: World Recent Past, Current & Future Analysis for Intravenous Administration Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 42: World Historic Review for Intravenous Administration Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 43: World 15-Year Perspective for Intravenous Administration Route by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 44: World Recent Past, Current & Future Analysis for Hospital Pharmacies Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 45: World Historic Review for Hospital Pharmacies Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 46: World 15-Year Perspective for Hospital Pharmacies Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 47: World Recent Past, Current & Future Analysis for Retail Pharmacies Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 48: World Historic Review for Retail Pharmacies Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 49: World 15-Year Perspective for Retail Pharmacies Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 50: World Recent Past, Current & Future Analysis for Online Pharmacies Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 51: World Historic Review for Online Pharmacies Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 52: World 15-Year Perspective for Online Pharmacies Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Growth Hormone Deficiency Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 53: USA Recent Past, Current & Future Analysis for Growth Hormone Deficiency by Treatment Type - Therapeutic, Recombinant Human Growth Hormone, Human Pituitary Gland Extracts and Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 54: USA Historic Review for Growth Hormone Deficiency by Treatment Type - Therapeutic, Recombinant Human Growth Hormone, Human Pituitary Gland Extracts and Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 55: USA 15-Year Perspective for Growth Hormone Deficiency by Treatment Type - Percentage Breakdown of Value Sales for Therapeutic, Recombinant Human Growth Hormone, Human Pituitary Gland Extracts and Surgery for the Years 2015, 2025 & 2030
  • TABLE 56: USA Recent Past, Current & Future Analysis for Growth Hormone Deficiency by Disease Indication - Other Disease Indications, Pediatric Growth Hormone Deficiency, Idiopathic Short Stature, Small for Gestational Age, Turner Syndrome and Adult Growth Hormone Deficiency - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: USA Historic Review for Growth Hormone Deficiency by Disease Indication - Other Disease Indications, Pediatric Growth Hormone Deficiency, Idiopathic Short Stature, Small for Gestational Age, Turner Syndrome and Adult Growth Hormone Deficiency Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 58: USA 15-Year Perspective for Growth Hormone Deficiency by Disease Indication - Percentage Breakdown of Value Sales for Other Disease Indications, Pediatric Growth Hormone Deficiency, Idiopathic Short Stature, Small for Gestational Age, Turner Syndrome and Adult Growth Hormone Deficiency for the Years 2015, 2025 & 2030
  • TABLE 59: USA Recent Past, Current & Future Analysis for Growth Hormone Deficiency by Administration Route - Subcutaneous Administration Route, Intramuscular Administration Route and Intravenous Administration Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 60: USA Historic Review for Growth Hormone Deficiency by Administration Route - Subcutaneous Administration Route, Intramuscular Administration Route and Intravenous Administration Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 61: USA 15-Year Perspective for Growth Hormone Deficiency by Administration Route - Percentage Breakdown of Value Sales for Subcutaneous Administration Route, Intramuscular Administration Route and Intravenous Administration Route for the Years 2015, 2025 & 2030
  • TABLE 62: USA Recent Past, Current & Future Analysis for Growth Hormone Deficiency by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: USA Historic Review for Growth Hormone Deficiency by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 64: USA 15-Year Perspective for Growth Hormone Deficiency by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 65: Canada Recent Past, Current & Future Analysis for Growth Hormone Deficiency by Treatment Type - Therapeutic, Recombinant Human Growth Hormone, Human Pituitary Gland Extracts and Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 66: Canada Historic Review for Growth Hormone Deficiency by Treatment Type - Therapeutic, Recombinant Human Growth Hormone, Human Pituitary Gland Extracts and Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 67: Canada 15-Year Perspective for Growth Hormone Deficiency by Treatment Type - Percentage Breakdown of Value Sales for Therapeutic, Recombinant Human Growth Hormone, Human Pituitary Gland Extracts and Surgery for the Years 2015, 2025 & 2030
  • TABLE 68: Canada Recent Past, Current & Future Analysis for Growth Hormone Deficiency by Disease Indication - Other Disease Indications, Pediatric Growth Hormone Deficiency, Idiopathic Short Stature, Small for Gestational Age, Turner Syndrome and Adult Growth Hormone Deficiency - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: Canada Historic Review for Growth Hormone Deficiency by Disease Indication - Other Disease Indications, Pediatric Growth Hormone Deficiency, Idiopathic Short Stature, Small for Gestational Age, Turner Syndrome and Adult Growth Hormone Deficiency Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 70: Canada 15-Year Perspective for Growth Hormone Deficiency by Disease Indication - Percentage Breakdown of Value Sales for Other Disease Indications, Pediatric Growth Hormone Deficiency, Idiopathic Short Stature, Small for Gestational Age, Turner Syndrome and Adult Growth Hormone Deficiency for the Years 2015, 2025 & 2030
  • TABLE 71: Canada Recent Past, Current & Future Analysis for Growth Hormone Deficiency by Administration Route - Subcutaneous Administration Route, Intramuscular Administration Route and Intravenous Administration Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 72: Canada Historic Review for Growth Hormone Deficiency by Administration Route - Subcutaneous Administration Route, Intramuscular Administration Route and Intravenous Administration Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 73: Canada 15-Year Perspective for Growth Hormone Deficiency by Administration Route - Percentage Breakdown of Value Sales for Subcutaneous Administration Route, Intramuscular Administration Route and Intravenous Administration Route for the Years 2015, 2025 & 2030
  • TABLE 74: Canada Recent Past, Current & Future Analysis for Growth Hormone Deficiency by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Canada Historic Review for Growth Hormone Deficiency by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 76: Canada 15-Year Perspective for Growth Hormone Deficiency by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
• JAPAN
  • Growth Hormone Deficiency Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 77: Japan Recent Past, Current & Future Analysis for Growth Hormone Deficiency by Treatment Type - Therapeutic, Recombinant Human Growth Hormone, Human Pituitary Gland Extracts and Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 78: Japan Historic Review for Growth Hormone Deficiency by Treatment Type - Therapeutic, Recombinant Human Growth Hormone, Human Pituitary Gland Extracts and Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 79: Japan 15-Year Perspective for Growth Hormone Deficiency by Treatment Type - Percentage Breakdown of Value Sales for Therapeutic, Recombinant Human Growth Hormone, Human Pituitary Gland Extracts and Surgery for the Years 2015, 2025 & 2030
  • TABLE 80: Japan Recent Past, Current & Future Analysis for Growth Hormone Deficiency by Disease Indication - Other Disease Indications, Pediatric Growth Hormone Deficiency, Idiopathic Short Stature, Small for Gestational Age, Turner Syndrome and Adult Growth Hormone Deficiency - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Japan Historic Review for Growth Hormone Deficiency by Disease Indication - Other Disease Indications, Pediatric Growth Hormone Deficiency, Idiopathic Short Stature, Small for Gestational Age, Turner Syndrome and Adult Growth Hormone Deficiency Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 82: Japan 15-Year Perspective for Growth Hormone Deficiency by Disease Indication - Percentage Breakdown of Value Sales for Other Disease Indications, Pediatric Growth Hormone Deficiency, Idiopathic Short Stature, Small for Gestational Age, Turner Syndrome and Adult Growth Hormone Deficiency for the Years 2015, 2025 & 2030
  • TABLE 83: Japan Recent Past, Current & Future Analysis for Growth Hormone Deficiency by Administration Route - Subcutaneous Administration Route, Intramuscular Administration Route and Intravenous Administration Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: Japan Historic Review for Growth Hormone Deficiency by Administration Route - Subcutaneous Administration Route, Intramuscular Administration Route and Intravenous Administration Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 85: Japan 15-Year Perspective for Growth Hormone Deficiency by Administration Route - Percentage Breakdown of Value Sales for Subcutaneous Administration Route, Intramuscular Administration Route and Intravenous Administration Route for the Years 2015, 2025 & 2030
  • TABLE 86: Japan Recent Past, Current & Future Analysis for Growth Hormone Deficiency by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: Japan Historic Review for Growth Hormone Deficiency by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 88: Japan 15-Year Perspective for Growth Hormone Deficiency by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
• CHINA
  • Growth Hormone Deficiency Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 89: China Recent Past, Current & Future Analysis for Growth Hormone Deficiency by Treatment Type - Therapeutic, Recombinant Human Growth Hormone, Human Pituitary Gland Extracts and Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 90: China Historic Review for Growth Hormone Deficiency by Treatment Type - Therapeutic, Recombinant Human Growth Hormone, Human Pituitary Gland Extracts and Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 91: China 15-Year Perspective for Growth Hormone Deficiency by Treatment Type - Percentage Breakdown of Value Sales for Therapeutic, Recombinant Human Growth Hormone, Human Pituitary Gland Extracts and Surgery for the Years 2015, 2025 & 2030
  • TABLE 92: China Recent Past, Current & Future Analysis for Growth Hormone Deficiency by Disease Indication - Other Disease Indications, Pediatric Growth Hormone Deficiency, Idiopathic Short Stature, Small for Gestational Age, Turner Syndrome and Adult Growth Hormone Deficiency - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: China Historic Review for Growth Hormone Deficiency by Disease Indication - Other Disease Indications, Pediatric Growth Hormone Deficiency, Idiopathic Short Stature, Small for Gestational Age, Turner Syndrome and Adult Growth Hormone Deficiency Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 94: China 15-Year Perspective for Growth Hormone Deficiency by Disease Indication - Percentage Breakdown of Value Sales for Other Disease Indications, Pediatric Growth Hormone Deficiency, Idiopathic Short Stature, Small for Gestational Age, Turner Syndrome and Adult Growth Hormone Deficiency for the Years 2015, 2025 & 2030
  • TABLE 95: China Recent Past, Current & Future Analysis for Growth Hormone Deficiency by Administration Route - Subcutaneous Administration Route, Intramuscular Administration Route and Intravenous Administration Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: China Historic Review for Growth Hormone Deficiency by Administration Route - Subcutaneous Administration Route, Intramuscular Administration Route and Intravenous Administration Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 97: China 15-Year Perspective for Growth Hormone Deficiency by Administration Route - Percentage Breakdown of Value Sales for Subcutaneous Administration Route, Intramuscular Administration Route and Intravenous Administration Route for the Years 2015, 2025 & 2030
  • TABLE 98: China Recent Past, Current & Future Analysis for Growth Hormone Deficiency by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: China Historic Review for Growth Hormone Deficiency by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 100: China 15-Year Perspective for Growth Hormone Deficiency by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
• EUROPE
  • Growth Hormone Deficiency Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 101: Europe Recent Past, Current & Future Analysis for Growth Hormone Deficiency by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 102: Europe Historic Review for Growth Hormone Deficiency by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 103: Europe 15-Year Perspective for Growth Hormone Deficiency by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 104: Europe Recent Past, Current & Future Analysis for Growth Hormone Deficiency by Treatment Type - Therapeutic, Recombinant Human Growth Hormone, Human Pituitary Gland Extracts and Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Europe Historic Review for Growth Hormone Deficiency by Treatment Type - Therapeutic, Recombinant Human Growth Hormone, Human Pituitary Gland Extracts and Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 106: Europe 15-Year Perspective for Growth Hormone Deficiency by Treatment Type - Percentage Breakdown of Value Sales for Therapeutic, Recombinant Human Growth Hormone, Human Pituitary Gland Extracts and Surgery for the Years 2015, 2025 & 2030
  • TABLE 107: Europe Recent Past, Current & Future Analysis for Growth Hormone Deficiency by Disease Indication - Other Disease Indications, Pediatric Growth Hormone Deficiency, Idiopathic Short Stature, Small for Gestational Age, Turner Syndrome and Adult Growth Hormone Deficiency - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 108: Europe Historic Review for Growth Hormone Deficiency by Disease Indication - Other Disease Indications, Pediatric Growth Hormone Deficiency, Idiopathic Short Stature, Small for Gestational Age, Turner Syndrome and Adult Growth Hormone Deficiency Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 109: Europe 15-Year Perspective for Growth Hormone Deficiency by Disease Indication - Percentage Breakdown of Value Sales for Other Disease Indications, Pediatric Growth Hormone Deficiency, Idiopathic Short Stature, Small for Gestational Age, Turner Syndrome and Adult Growth Hormone Deficiency for the Years 2015, 2025 & 2030
  • TABLE 110: Europe Recent Past, Current & Future Analysis for Growth Hormone Deficiency by Administration Route - Subcutaneous Administration Route, Intramuscular Administration Route and Intravenous Administration Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 111: Europe Historic Review for Growth Hormone Deficiency by Administration Route - Subcutaneous Administration Route, Intramuscular Administration Route and Intravenous Administration Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 112: Europe 15-Year Perspective for Growth Hormone Deficiency by Administration Route - Percentage Breakdown of Value Sales for Subcutaneous Administration Route, Intramuscular Administration Route and Intravenous Administration Route for the Years 2015, 2025 & 2030
  • TABLE 113: Europe Recent Past, Current & Future Analysis for Growth Hormone Deficiency by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 114: Europe Historic Review for Growth Hormone Deficiency by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 115: Europe 15-Year Perspective for Growth Hormone Deficiency by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
• FRANCE
  • Growth Hormone Deficiency Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 116: France Recent Past, Current & Future Analysis for Growth Hormone Deficiency by Treatment Type - Therapeutic, Recombinant Human Growth Hormone, Human Pituitary Gland Extracts and Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: France Historic Review for Growth Hormone Deficiency by Treatment Type - Therapeutic, Recombinant Human Growth Hormone, Human Pituitary Gland Extracts and Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 118: France 15-Year Perspective for Growth Hormone Deficiency by Treatment Type - Percentage Breakdown of Value Sales for Therapeutic, Recombinant Human Growth Hormone, Human Pituitary Gland Extracts and Surgery for the Years 2015, 2025 & 2030
  • TABLE 119: France Recent Past, Current & Future Analysis for Growth Hormone Deficiency by Disease Indication - Other Disease Indications, Pediatric Growth Hormone Deficiency, Idiopathic Short Stature, Small for Gestational Age, Turner Syndrome and Adult Growth Hormone Deficiency - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 120: France Historic Review for Growth Hormone Deficiency by Disease Indication - Other Disease Indications, Pediatric Growth Hormone Deficiency, Idiopathic Short Stature, Small for Gestational Age, Turner Syndrome and Adult Growth Hormone Deficiency Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 121: France 15-Year Perspective for Growth Hormone Deficiency by Disease Indication - Percentage Breakdown of Value Sales for Other Disease Indications, Pediatric Growth Hormone Deficiency, Idiopathic Short Stature, Small for Gestational Age, Turner Syndrome and Adult Growth Hormone Deficiency for the Years 2015, 2025 & 2030
  • TABLE 122: France Recent Past, Current & Future Analysis for Growth Hormone Deficiency by Administration Route - Subcutaneous Administration Route, Intramuscular Administration Route and Intravenous Administration Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 123: France Historic Review for Growth Hormone Deficiency by Administration Route - Subcutaneous Administration Route, Intramuscular Administration Route and Intravenous Administration Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 124: France 15-Year Perspective for Growth Hormone Deficiency by Administration Route - Percentage Breakdown of Value Sales for Subcutaneous Administration Route, Intramuscular Administration Route and Intravenous Administration Route for the Years 2015, 2025 & 2030
  • TABLE 125: France Recent Past, Current & Future Analysis for Growth Hormone Deficiency by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 126: France Historic Review for Growth Hormone Deficiency by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 127: France 15-Year Perspective for Growth Hormone Deficiency by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
• GERMANY
  • Growth Hormone Deficiency Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 128: Germany Recent Past, Current & Future Analysis for Growth Hormone Deficiency by Treatment Type - Therapeutic, Recombinant Human Growth Hormone, Human Pituitary Gland Extracts and Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Germany Historic Review for Growth Hormone Deficiency by Treatment Type - Therapeutic, Recombinant Human Growth Hormone, Human Pituitary Gland Extracts and Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 130: Germany 15-Year Perspective for Growth Hormone Deficiency by Treatment Type - Percentage Breakdown of Value Sales for Therapeutic, Recombinant Human Growth Hormone, Human Pituitary Gland Extracts and Surgery for the Years 2015, 2025 & 2030
  • TABLE 131: Germany Recent Past, Current & Future Analysis for Growth Hormone Deficiency by Disease Indication - Other Disease Indications, Pediatric Growth Hormone Deficiency, Idiopathic Short Stature, Small for Gestational Age, Turner Syndrome and Adult Growth Hormone Deficiency - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Germany Historic Review for Growth Hormone Deficiency by Disease Indication - Other Disease Indications, Pediatric Growth Hormone Deficiency, Idiopathic Short Stature, Small for Gestational Age, Turner Syndrome and Adult Growth Hormone Deficiency Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 133: Germany 15-Year Perspective for Growth Hormone Deficiency by Disease Indication - Percentage Breakdown of Value Sales for Other Disease Indications, Pediatric Growth Hormone Deficiency, Idiopathic Short Stature, Small for Gestational Age, Turner Syndrome and Adult Growth Hormone Deficiency for the Years 2015, 2025 & 2030
  • TABLE 134: Germany Recent Past, Current & Future Analysis for Growth Hormone Deficiency by Administration Route - Subcutaneous Administration Route, Intramuscular Administration Route and Intravenous Administration Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Germany Historic Review for Growth Hormone Deficiency by Administration Route - Subcutaneous Administration Route, Intramuscular Administration Route and Intravenous Administration Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 136: Germany 15-Year Perspective for Growth Hormone Deficiency by Administration Route - Percentage Breakdown of Value Sales for Subcutaneous Administration Route, Intramuscular Administration Route and Intravenous Administration Route for the Years 2015, 2025 & 2030
  • TABLE 137: Germany Recent Past, Current & Future Analysis for Growth Hormone Deficiency by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Germany Historic Review for Growth Hormone Deficiency by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 139: Germany 15-Year Perspective for Growth Hormone Deficiency by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 140: Italy Recent Past, Current & Future Analysis for Growth Hormone Deficiency by Treatment Type - Therapeutic, Recombinant Human Growth Hormone, Human Pituitary Gland Extracts and Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Italy Historic Review for Growth Hormone Deficiency by Treatment Type - Therapeutic, Recombinant Human Growth Hormone, Human Pituitary Gland Extracts and Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 142: Italy 15-Year Perspective for Growth Hormone Deficiency by Treatment Type - Percentage Breakdown of Value Sales for Therapeutic, Recombinant Human Growth Hormone, Human Pituitary Gland Extracts and Surgery for the Years 2015, 2025 & 2030
  • TABLE 143: Italy Recent Past, Current & Future Analysis for Growth Hormone Deficiency by Disease Indication - Other Disease Indications, Pediatric Growth Hormone Deficiency, Idiopathic Short Stature, Small for Gestational Age, Turner Syndrome and Adult Growth Hormone Deficiency - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Italy Historic Review for Growth Hormone Deficiency by Disease Indication - Other Disease Indications, Pediatric Growth Hormone Deficiency, Idiopathic Short Stature, Small for Gestational Age, Turner Syndrome and Adult Growth Hormone Deficiency Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 145: Italy 15-Year Perspective for Growth Hormone Deficiency by Disease Indication - Percentage Breakdown of Value Sales for Other Disease Indications, Pediatric Growth Hormone Deficiency, Idiopathic Short Stature, Small for Gestational Age, Turner Syndrome and Adult Growth Hormone Deficiency for the Years 2015, 2025 & 2030
  • TABLE 146: Italy Recent Past, Current & Future Analysis for Growth Hormone Deficiency by Administration Route - Subcutaneous Administration Route, Intramuscular Administration Route and Intravenous Administration Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Italy Historic Review for Growth Hormone Deficiency by Administration Route - Subcutaneous Administration Route, Intramuscular Administration Route and Intravenous Administration Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 148: Italy 15-Year Perspective for Growth Hormone Deficiency by Administration Route - Percentage Breakdown of Value Sales for Subcutaneous Administration Route, Intramuscular Administration Route and Intravenous Administration Route for the Years 2015, 2025 & 2030
  • TABLE 149: Italy Recent Past, Current & Future Analysis for Growth Hormone Deficiency by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Italy Historic Review for Growth Hormone Deficiency by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 151: Italy 15-Year Perspective for Growth Hormone Deficiency by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Growth Hormone Deficiency Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 152: UK Recent Past, Current & Future Analysis for Growth Hormone Deficiency by Treatment Type - Therapeutic, Recombinant Human Growth Hormone, Human Pituitary Gland Extracts and Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 153: UK Historic Review for Growth Hormone Deficiency by Treatment Type - Therapeutic, Recombinant Human Growth Hormone, Human Pituitary Gland Extracts and Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 154: UK 15-Year Perspective for Growth Hormone Deficiency by Treatment Type - Percentage Breakdown of Value Sales for Therapeutic, Recombinant Human Growth Hormone, Human Pituitary Gland Extracts and Surgery for the Years 2015, 2025 & 2030
  • TABLE 155: UK Recent Past, Current & Future Analysis for Growth Hormone Deficiency by Disease Indication - Other Disease Indications, Pediatric Growth Hormone Deficiency, Idiopathic Short Stature, Small for Gestational Age, Turner Syndrome and Adult Growth Hormone Deficiency - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 156: UK Historic Review for Growth Hormone Deficiency by Disease Indication - Other Disease Indications, Pediatric Growth Hormone Deficiency, Idiopathic Short Stature, Small for Gestational Age, Turner Syndrome and Adult Growth Hormone Deficiency Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 157: UK 15-Year Perspective for Growth Hormone Deficiency by Disease Indication - Percentage Breakdown of Value Sales for Other Disease Indications, Pediatric Growth Hormone Deficiency, Idiopathic Short Stature, Small for Gestational Age, Turner Syndrome and Adult Growth Hormone Deficiency for the Years 2015, 2025 & 2030
  • TABLE 158: UK Recent Past, Current & Future Analysis for Growth Hormone Deficiency by Administration Route - Subcutaneous Administration Route, Intramuscular Administration Route and Intravenous Administration Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 159: UK Historic Review for Growth Hormone Deficiency by Administration Route - Subcutaneous Administration Route, Intramuscular Administration Route and Intravenous Administration Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 160: UK 15-Year Perspective for Growth Hormone Deficiency by Administration Route - Percentage Breakdown of Value Sales for Subcutaneous Administration Route, Intramuscular Administration Route and Intravenous Administration Route for the Years 2015, 2025 & 2030
  • TABLE 161: UK Recent Past, Current & Future Analysis for Growth Hormone Deficiency by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 162: UK Historic Review for Growth Hormone Deficiency by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 163: UK 15-Year Perspective for Growth Hormone Deficiency by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 164: Spain Recent Past, Current & Future Analysis for Growth Hormone Deficiency by Treatment Type - Therapeutic, Recombinant Human Growth Hormone, Human Pituitary Gland Extracts and Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Spain Historic Review for Growth Hormone Deficiency by Treatment Type - Therapeutic, Recombinant Human Growth Hormone, Human Pituitary Gland Extracts and Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 166: Spain 15-Year Perspective for Growth Hormone Deficiency by Treatment Type - Percentage Breakdown of Value Sales for Therapeutic, Recombinant Human Growth Hormone, Human Pituitary Gland Extracts and Surgery for the Years 2015, 2025 & 2030
  • TABLE 167: Spain Recent Past, Current & Future Analysis for Growth Hormone Deficiency by Disease Indication - Other Disease Indications, Pediatric Growth Hormone Deficiency, Idiopathic Short Stature, Small for Gestational Age, Turner Syndrome and Adult Growth Hormone Deficiency - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Spain Historic Review for Growth Hormone Deficiency by Disease Indication - Other Disease Indications, Pediatric Growth Hormone Deficiency, Idiopathic Short Stature, Small for Gestational Age, Turner Syndrome and Adult Growth Hormone Deficiency Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 169: Spain 15-Year Perspective for Growth Hormone Deficiency by Disease Indication - Percentage Breakdown of Value Sales for Other Disease Indications, Pediatric Growth Hormone Deficiency, Idiopathic Short Stature, Small for Gestational Age, Turner Syndrome and Adult Growth Hormone Deficiency for the Years 2015, 2025 & 2030
  • TABLE 170: Spain Recent Past, Current & Future Analysis for Growth Hormone Deficiency by Administration Route - Subcutaneous Administration Route, Intramuscular Administration Route and Intravenous Administration Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 171: Spain Historic Review for Growth Hormone Deficiency by Administration Route - Subcutaneous Administration Route, Intramuscular Administration Route and Intravenous Administration Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 172: Spain 15-Year Perspective for Growth Hormone Deficiency by Administration Route - Percentage Breakdown of Value Sales for Subcutaneous Administration Route, Intramuscular Administration Route and Intravenous Administration Route for the Years 2015, 2025 & 2030
  • TABLE 173: Spain Recent Past, Current & Future Analysis for Growth Hormone Deficiency by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 174: Spain Historic Review for Growth Hormone Deficiency by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 175: Spain 15-Year Perspective for Growth Hormone Deficiency by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 176: Russia Recent Past, Current & Future Analysis for Growth Hormone Deficiency by Treatment Type - Therapeutic, Recombinant Human Growth Hormone, Human Pituitary Gland Extracts and Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 177: Russia Historic Review for Growth Hormone Deficiency by Treatment Type - Therapeutic, Recombinant Human Growth Hormone, Human Pituitary Gland Extracts and Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 178: Russia 15-Year Perspective for Growth Hormone Deficiency by Treatment Type - Percentage Breakdown of Value Sales for Therapeutic, Recombinant Human Growth Hormone, Human Pituitary Gland Extracts and Surgery for the Years 2015, 2025 & 2030
  • TABLE 179: Russia Recent Past, Current & Future Analysis for Growth Hormone Deficiency by Disease Indication - Other Disease Indications, Pediatric Growth Hormone Deficiency, Idiopathic Short Stature, Small for Gestational Age, Turner Syndrome and Adult Growth Hormone Deficiency - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 180: Russia Historic Review for Growth Hormone Deficiency by Disease Indication - Other Disease Indications, Pediatric Growth Hormone Deficiency, Idiopathic Short Stature, Small for Gestational Age, Turner Syndrome and Adult Growth Hormone Deficiency Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 181: Russia 15-Year Perspective for Growth Hormone Deficiency by Disease Indication - Percentage Breakdown of Value Sales for Other Disease Indications, Pediatric Growth Hormone Deficiency, Idiopathic Short Stature, Small for Gestational Age, Turner Syndrome and Adult Growth Hormone Deficiency for the Years 2015, 2025 & 2030
  • TABLE 182: Russia Recent Past, Current & Future Analysis for Growth Hormone Deficiency by Administration Route - Subcutaneous Administration Route, Intramuscular Administration Route and Intravenous Administration Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 183: Russia Historic Review for Growth Hormone Deficiency by Administration Route - Subcutaneous Administration Route, Intramuscular Administration Route and Intravenous Administration Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 184: Russia 15-Year Perspective for Growth Hormone Deficiency by Administration Route - Percentage Breakdown of Value Sales for Subcutaneous Administration Route, Intramuscular Administration Route and Intravenous Administration Route for the Years 2015, 2025 & 2030
  • TABLE 185: Russia Recent Past, Current & Future Analysis for Growth Hormone Deficiency by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 186: Russia Historic Review for Growth Hormone Deficiency by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 187: Russia 15-Year Perspective for Growth Hormone Deficiency by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 188: Rest of Europe Recent Past, Current & Future Analysis for Growth Hormone Deficiency by Treatment Type - Therapeutic, Recombinant Human Growth Hormone, Human Pituitary Gland Extracts and Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Rest of Europe Historic Review for Growth Hormone Deficiency by Treatment Type - Therapeutic, Recombinant Human Growth Hormone, Human Pituitary Gland Extracts and Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 190: Rest of Europe 15-Year Perspective for Growth Hormone Deficiency by Treatment Type - Percentage Breakdown of Value Sales for Therapeutic, Recombinant Human Growth Hormone, Human Pituitary Gland Extracts and Surgery for the Years 2015, 2025 & 2030
  • TABLE 191: Rest of Europe Recent Past, Current & Future Analysis for Growth Hormone Deficiency by Disease Indication - Other Disease Indications, Pediatric Growth Hormone Deficiency, Idiopathic Short Stature, Small for Gestational Age, Turner Syndrome and Adult Growth Hormone Deficiency - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Rest of Europe Historic Review for Growth Hormone Deficiency by Disease Indication - Other Disease Indications, Pediatric Growth Hormone Deficiency, Idiopathic Short Stature, Small for Gestational Age, Turner Syndrome and Adult Growth Hormone Deficiency Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 193: Rest of Europe 15-Year Perspective for Growth Hormone Deficiency by Disease Indication - Percentage Breakdown of Value Sales for Other Disease Indications, Pediatric Growth Hormone Deficiency, Idiopathic Short Stature, Small for Gestational Age, Turner Syndrome and Adult Growth Hormone Deficiency for the Years 2015, 2025 & 2030
  • TABLE 194: Rest of Europe Recent Past, Current & Future Analysis for Growth Hormone Deficiency by Administration Route - Subcutaneous Administration Route, Intramuscular Administration Route and Intravenous Administration Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Rest of Europe Historic Review for Growth Hormone Deficiency by Administration Route - Subcutaneous Administration Route, Intramuscular Administration Route and Intravenous Administration Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 196: Rest of Europe 15-Year Perspective for Growth Hormone Deficiency by Administration Route - Percentage Breakdown of Value Sales for Subcutaneous Administration Route, Intramuscular Administration Route and Intravenous Administration Route for the Years 2015, 2025 & 2030
  • TABLE 197: Rest of Europe Recent Past, Current & Future Analysis for Growth Hormone Deficiency by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Rest of Europe Historic Review for Growth Hormone Deficiency by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 199: Rest of Europe 15-Year Perspective for Growth Hormone Deficiency by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Growth Hormone Deficiency Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 200: Asia-Pacific Recent Past, Current & Future Analysis for Growth Hormone Deficiency by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 201: Asia-Pacific Historic Review for Growth Hormone Deficiency by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 202: Asia-Pacific 15-Year Perspective for Growth Hormone Deficiency by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 203: Asia-Pacific Recent Past, Current & Future Analysis for Growth Hormone Deficiency by Treatment Type - Therapeutic, Recombinant Human Growth Hormone, Human Pituitary Gland Extracts and Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Asia-Pacific Historic Review for Growth Hormone Deficiency by Treatment Type - Therapeutic, Recombinant Human Growth Hormone, Human Pituitary Gland Extracts and Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 205: Asia-Pacific 15-Year Perspective for Growth Hormone Deficiency by Treatment Type - Percentage Breakdown of Value Sales for Therapeutic, Recombinant Human Growth Hormone, Human Pituitary Gland Extracts and Surgery for the Years 2015, 2025 & 2030
  • TABLE 206: Asia-Pacific Recent Past, Current & Future Analysis for Growth Hormone Deficiency by Disease Indication - Other Disease Indications, Pediatric Growth Hormone Deficiency, Idiopathic Short Stature, Small for Gestational Age, Turner Syndrome and Adult Growth Hormone Deficiency - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Asia-Pacific Historic Review for Growth Hormone Deficiency by Disease Indication - Other Disease Indications, Pediatric Growth Hormone Deficiency, Idiopathic Short Stature, Small for Gestational Age, Turner Syndrome and Adult Growth Hormone Deficiency Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 208: Asia-Pacific 15-Year Perspective for Growth Hormone Deficiency by Disease Indication - Percentage Breakdown of Value Sales for Other Disease Indications, Pediatric Growth Hormone Deficiency, Idiopathic Short Stature, Small for Gestational Age, Turner Syndrome and Adult Growth Hormone Deficiency for the Years 2015, 2025 & 2030
  • TABLE 209: Asia-Pacific Recent Past, Current & Future Analysis for Growth Hormone Deficiency by Administration Route - Subcutaneous Administration Route, Intramuscular Administration Route and Intravenous Administration Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Asia-Pacific Historic Review for Growth Hormone Deficiency by Administration Route - Subcutaneous Administration Route, Intramuscular Administration Route and Intravenous Administration Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 211: Asia-Pacific 15-Year Perspective for Growth Hormone Deficiency by Administration Route - Percentage Breakdown of Value Sales for Subcutaneous Administration Route, Intramuscular Administration Route and Intravenous Administration Route for the Years 2015, 2025 & 2030
  • TABLE 212: Asia-Pacific Recent Past, Current & Future Analysis for Growth Hormone Deficiency by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Asia-Pacific Historic Review for Growth Hormone Deficiency by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 214: Asia-Pacific 15-Year Perspective for Growth Hormone Deficiency by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Growth Hormone Deficiency Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 215: Australia Recent Past, Current & Future Analysis for Growth Hormone Deficiency by Treatment Type - Therapeutic, Recombinant Human Growth Hormone, Human Pituitary Gland Extracts and Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Australia Historic Review for Growth Hormone Deficiency by Treatment Type - Therapeutic, Recombinant Human Growth Hormone, Human Pituitary Gland Extracts and Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 217: Australia 15-Year Perspective for Growth Hormone Deficiency by Treatment Type - Percentage Breakdown of Value Sales for Therapeutic, Recombinant Human Growth Hormone, Human Pituitary Gland Extracts and Surgery for the Years 2015, 2025 & 2030
  • TABLE 218: Australia Recent Past, Current & Future Analysis for Growth Hormone Deficiency by Disease Indication - Other Disease Indications, Pediatric Growth Hormone Deficiency, Idiopathic Short Stature, Small for Gestational Age, Turner Syndrome and Adult Growth Hormone Deficiency - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Australia Historic Review for Growth Hormone Deficiency by Disease Indication - Other Disease Indications, Pediatric Growth Hormone Deficiency, Idiopathic Short Stature, Small for Gestational Age, Turner Syndrome and Adult Growth Hormone Deficiency Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 220: Australia 15-Year Perspective for Growth Hormone Deficiency by Disease Indication - Percentage Breakdown of Value Sales for Other Disease Indications, Pediatric Growth Hormone Deficiency, Idiopathic Short Stature, Small for Gestational Age, Turner Syndrome and Adult Growth Hormone Deficiency for the Years 2015, 2025 & 2030
  • TABLE 221: Australia Recent Past, Current & Future Analysis for Growth Hormone Deficiency by Administration Route - Subcutaneous Administration Route, Intramuscular Administration Route and Intravenous Administration Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Australia Historic Review for Growth Hormone Deficiency by Administration Route - Subcutaneous Administration Route, Intramuscular Administration Route and Intravenous Administration Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 223: Australia 15-Year Perspective for Growth Hormone Deficiency by Administration Route - Percentage Breakdown of Value Sales for Subcutaneous Administration Route, Intramuscular Administration Route and Intravenous Administration Route for the Years 2015, 2025 & 2030
  • TABLE 224: Australia Recent Past, Current & Future Analysis for Growth Hormone Deficiency by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Australia Historic Review for Growth Hormone Deficiency by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 226: Australia 15-Year Perspective for Growth Hormone Deficiency by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
• INDIA
  • Growth Hormone Deficiency Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 227: India Recent Past, Current & Future Analysis for Growth Hormone Deficiency by Treatment Type - Therapeutic, Recombinant Human Growth Hormone, Human Pituitary Gland Extracts and Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 228: India Historic Review for Growth Hormone Deficiency by Treatment Type - Therapeutic, Recombinant Human Growth Hormone, Human Pituitary Gland Extracts and Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 229: India 15-Year Perspective for Growth Hormone Deficiency by Treatment Type - Percentage Breakdown of Value Sales for Therapeutic, Recombinant Human Growth Hormone, Human Pituitary Gland Extracts and Surgery for the Years 2015, 2025 & 2030
  • TABLE 230: India Recent Past, Current & Future Analysis for Growth Hormone Deficiency by Disease Indication - Other Disease Indications, Pediatric Growth Hormone Deficiency, Idiopathic Short Stature, Small for Gestational Age, Turner Syndrome and Adult Growth Hormone Deficiency - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 231: India Historic Review for Growth Hormone Deficiency by Disease Indication - Other Disease Indications, Pediatric Growth Hormone Deficiency, Idiopathic Short Stature, Small for Gestational Age, Turner Syndrome and Adult Growth Hormone Deficiency Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 232: India 15-Year Perspective for Growth Hormone Deficiency by Disease Indication - Percentage Breakdown of Value Sales for Other Disease Indications, Pediatric Growth Hormone Deficiency, Idiopathic Short Stature, Small for Gestational Age, Turner Syndrome and Adult Growth Hormone Deficiency for the Years 2015, 2025 & 2030
  • TABLE 233: India Recent Past, Current & Future Analysis for Growth Hormone Deficiency by Administration Route - Subcutaneous Administration Route, Intramuscular Administration Route and Intravenous Administration Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 234: India Historic Review for Growth Hormone Deficiency by Administration Route - Subcutaneous Administration Route, Intramuscular Administration Route and Intravenous Administration Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 235: India 15-Year Perspective for Growth Hormone Deficiency by Administration Route - Percentage Breakdown of Value Sales for Subcutaneous Administration Route, Intramuscular Administration Route and Intravenous Administration Route for the Years 2015, 2025 & 2030
  • TABLE 236: India Recent Past, Current & Future Analysis for Growth Hormone Deficiency by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 237: India Historic Review for Growth Hormone Deficiency by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 238: India 15-Year Perspective for Growth Hormone Deficiency by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 239: South Korea Recent Past, Current & Future Analysis for Growth Hormone Deficiency by Treatment Type - Therapeutic, Recombinant Human Growth Hormone, Human Pituitary Gland Extracts and Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 240: South Korea Historic Review for Growth Hormone Deficiency by Treatment Type - Therapeutic, Recombinant Human Growth Hormone, Human Pituitary Gland Extracts and Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 241: South Korea 15-Year Perspective for Growth Hormone Deficiency by Treatment Type - Percentage Breakdown of Value Sales for Therapeutic, Recombinant Human Growth Hormone, Human Pituitary Gland Extracts and Surgery for the Years 2015, 2025 & 2030
  • TABLE 242: South Korea Recent Past, Current & Future Analysis for Growth Hormone Deficiency by Disease Indication - Other Disease Indications, Pediatric Growth Hormone Deficiency, Idiopathic Short Stature, Small for Gestational Age, Turner Syndrome and Adult Growth Hormone Deficiency - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 243: South Korea Historic Review for Growth Hormone Deficiency by Disease Indication - Other Disease Indications, Pediatric Growth Hormone Deficiency, Idiopathic Short Stature, Small for Gestational Age, Turner Syndrome and Adult Growth Hormone Deficiency Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 244: South Korea 15-Year Perspective for Growth Hormone Deficiency by Disease Indication - Percentage Breakdown of Value Sales for Other Disease Indications, Pediatric Growth Hormone Deficiency, Idiopathic Short Stature, Small for Gestational Age, Turner Syndrome and Adult Growth Hormone Deficiency for the Years 2015, 2025 & 2030
  • TABLE 245: South Korea Recent Past, Current & Future Analysis for Growth Hormone Deficiency by Administration Route - Subcutaneous Administration Route, Intramuscular Administration Route and Intravenous Administration Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 246: South Korea Historic Review for Growth Hormone Deficiency by Administration Route - Subcutaneous Administration Route, Intramuscular Administration Route and Intravenous Administration Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 247: South Korea 15-Year Perspective for Growth Hormone Deficiency by Administration Route - Percentage Breakdown of Value Sales for Subcutaneous Administration Route, Intramuscular Administration Route and Intravenous Administration Route for the Years 2015, 2025 & 2030
  • TABLE 248: South Korea Recent Past, Current & Future Analysis for Growth Hormone Deficiency by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 249: South Korea Historic Review for Growth Hormone Deficiency by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 250: South Korea 15-Year Perspective for Growth Hormone Deficiency by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 251: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Growth Hormone Deficiency by Treatment Type - Therapeutic, Recombinant Human Growth Hormone, Human Pituitary Gland Extracts and Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Rest of Asia-Pacific Historic Review for Growth Hormone Deficiency by Treatment Type - Therapeutic, Recombinant Human Growth Hormone, Human Pituitary Gland Extracts and Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 253: Rest of Asia-Pacific 15-Year Perspective for Growth Hormone Deficiency by Treatment Type - Percentage Breakdown of Value Sales for Therapeutic, Recombinant Human Growth Hormone, Human Pituitary Gland Extracts and Surgery for the Years 2015, 2025 & 2030
  • TABLE 254: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Growth Hormone Deficiency by Disease Indication - Other Disease Indications, Pediatric Growth Hormone Deficiency, Idiopathic Short Stature, Small for Gestational Age, Turner Syndrome and Adult Growth Hormone Deficiency - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Rest of Asia-Pacific Historic Review for Growth Hormone Deficiency by Disease Indication - Other Disease Indications, Pediatric Growth Hormone Deficiency, Idiopathic Short Stature, Small for Gestational Age, Turner Syndrome and Adult Growth Hormone Deficiency Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 256: Rest of Asia-Pacific 15-Year Perspective for Growth Hormone Deficiency by Disease Indication - Percentage Breakdown of Value Sales for Other Disease Indications, Pediatric Growth Hormone Deficiency, Idiopathic Short Stature, Small for Gestational Age, Turner Syndrome and Adult Growth Hormone Deficiency for the Years 2015, 2025 & 2030
  • TABLE 257: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Growth Hormone Deficiency by Administration Route - Subcutaneous Administration Route, Intramuscular Administration Route and Intravenous Administration Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Rest of Asia-Pacific Historic Review for Growth Hormone Deficiency by Administration Route - Subcutaneous Administration Route, Intramuscular Administration Route and Intravenous Administration Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 259: Rest of Asia-Pacific 15-Year Perspective for Growth Hormone Deficiency by Administration Route - Percentage Breakdown of Value Sales for Subcutaneous Administration Route, Intramuscular Administration Route and Intravenous Administration Route for the Years 2015, 2025 & 2030
  • TABLE 260: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Growth Hormone Deficiency by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Rest of Asia-Pacific Historic Review for Growth Hormone Deficiency by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 262: Rest of Asia-Pacific 15-Year Perspective for Growth Hormone Deficiency by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Growth Hormone Deficiency Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 263: Latin America Recent Past, Current & Future Analysis for Growth Hormone Deficiency by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 264: Latin America Historic Review for Growth Hormone Deficiency by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 265: Latin America 15-Year Perspective for Growth Hormone Deficiency by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 266: Latin America Recent Past, Current & Future Analysis for Growth Hormone Deficiency by Treatment Type - Therapeutic, Recombinant Human Growth Hormone, Human Pituitary Gland Extracts and Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Latin America Historic Review for Growth Hormone Deficiency by Treatment Type - Therapeutic, Recombinant Human Growth Hormone, Human Pituitary Gland Extracts and Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 268: Latin America 15-Year Perspective for Growth Hormone Deficiency by Treatment Type - Percentage Breakdown of Value Sales for Therapeutic, Recombinant Human Growth Hormone, Human Pituitary Gland Extracts and Surgery for the Years 2015, 2025 & 2030
  • TABLE 269: Latin America Recent Past, Current & Future Analysis for Growth Hormone Deficiency by Disease Indication - Other Disease Indications, Pediatric Growth Hormone Deficiency, Idiopathic Short Stature, Small for Gestational Age, Turner Syndrome and Adult Growth Hormone Deficiency - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Latin America Historic Review for Growth Hormone Deficiency by Disease Indication - Other Disease Indications, Pediatric Growth Hormone Deficiency, Idiopathic Short Stature, Small for Gestational Age, Turner Syndrome and Adult Growth Hormone Deficiency Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 271: Latin America 15-Year Perspective for Growth Hormone Deficiency by Disease Indication - Percentage Breakdown of Value Sales for Other Disease Indications, Pediatric Growth Hormone Deficiency, Idiopathic Short Stature, Small for Gestational Age, Turner Syndrome and Adult Growth Hormone Deficiency for the Years 2015, 2025 & 2030
  • TABLE 272: Latin America Recent Past, Current & Future Analysis for Growth Hormone Deficiency by Administration Route - Subcutaneous Administration Route, Intramuscular Administration Route and Intravenous Administration Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Latin America Historic Review for Growth Hormone Deficiency by Administration Route - Subcutaneous Administration Route, Intramuscular Administration Route and Intravenous Administration Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 274: Latin America 15-Year Perspective for Growth Hormone Deficiency by Administration Route - Percentage Breakdown of Value Sales for Subcutaneous Administration Route, Intramuscular Administration Route and Intravenous Administration Route for the Years 2015, 2025 & 2030
  • TABLE 275: Latin America Recent Past, Current & Future Analysis for Growth Hormone Deficiency by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Latin America Historic Review for Growth Hormone Deficiency by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 277: Latin America 15-Year Perspective for Growth Hormone Deficiency by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 278: Argentina Recent Past, Current & Future Analysis for Growth Hormone Deficiency by Treatment Type - Therapeutic, Recombinant Human Growth Hormone, Human Pituitary Gland Extracts and Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Argentina Historic Review for Growth Hormone Deficiency by Treatment Type - Therapeutic, Recombinant Human Growth Hormone, Human Pituitary Gland Extracts and Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 280: Argentina 15-Year Perspective for Growth Hormone Deficiency by Treatment Type - Percentage Breakdown of Value Sales for Therapeutic, Recombinant Human Growth Hormone, Human Pituitary Gland Extracts and Surgery for the Years 2015, 2025 & 2030
  • TABLE 281: Argentina Recent Past, Current & Future Analysis for Growth Hormone Deficiency by Disease Indication - Other Disease Indications, Pediatric Growth Hormone Deficiency, Idiopathic Short Stature, Small for Gestational Age, Turner Syndrome and Adult Growth Hormone Deficiency - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Argentina Historic Review for Growth Hormone Deficiency by Disease Indication - Other Disease Indications, Pediatric Growth Hormone Deficiency, Idiopathic Short Stature, Small for Gestational Age, Turner Syndrome and Adult Growth Hormone Deficiency Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 283: Argentina 15-Year Perspective for Growth Hormone Deficiency by Disease Indication - Percentage Breakdown of Value Sales for Other Disease Indications, Pediatric Growth Hormone Deficiency, Idiopathic Short Stature, Small for Gestational Age, Turner Syndrome and Adult Growth Hormone Deficiency for the Years 2015, 2025 & 2030
  • TABLE 284: Argentina Recent Past, Current & Future Analysis for Growth Hormone Deficiency by Administration Route - Subcutaneous Administration Route, Intramuscular Administration Route and Intravenous Administration Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 285: Argentina Historic Review for Growth Hormone Deficiency by Administration Route - Subcutaneous Administration Route, Intramuscular Administration Route and Intravenous Administration Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 286: Argentina 15-Year Perspective for Growth Hormone Deficiency by Administration Route - Percentage Breakdown of Value Sales for Subcutaneous Administration Route, Intramuscular Administration Route and Intravenous Administration Route for the Years 2015, 2025 & 2030
  • TABLE 287: Argentina Recent Past, Current & Future Analysis for Growth Hormone Deficiency by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 288: Argentina Historic Review for Growth Hormone Deficiency by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 289: Argentina 15-Year Perspective for Growth Hormone Deficiency by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 290: Brazil Recent Past, Current & Future Analysis for Growth Hormone Deficiency by Treatment Type - Therapeutic, Recombinant Human Growth Hormone, Human Pituitary Gland Extracts and Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 291: Brazil Historic Review for Growth Hormone Deficiency by Treatment Type - Therapeutic, Recombinant Human Growth Hormone, Human Pituitary Gland Extracts and Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 292: Brazil 15-Year Perspective for Growth Hormone Deficiency by Treatment Type - Percentage Breakdown of Value Sales for Therapeutic, Recombinant Human Growth Hormone, Human Pituitary Gland Extracts and Surgery for the Years 2015, 2025 & 2030
  • TABLE 293: Brazil Recent Past, Current & Future Analysis for Growth Hormone Deficiency by Disease Indication - Other Disease Indications, Pediatric Growth Hormone Deficiency, Idiopathic Short Stature, Small for Gestational Age, Turner Syndrome and Adult Growth Hormone Deficiency - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Brazil Historic Review for Growth Hormone Deficiency by Disease Indication - Other Disease Indications, Pediatric Growth Hormone Deficiency, Idiopathic Short Stature, Small for Gestational Age, Turner Syndrome and Adult Growth Hormone Deficiency Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 295: Brazil 15-Year Perspective for Growth Hormone Deficiency by Disease Indication - Percentage Breakdown of Value Sales for Other Disease Indications, Pediatric Growth Hormone Deficiency, Idiopathic Short Stature, Small for Gestational Age, Turner Syndrome and Adult Growth Hormone Deficiency for the Years 2015, 2025 & 2030
  • TABLE 296: Brazil Recent Past, Current & Future Analysis for Growth Hormone Deficiency by Administration Route - Subcutaneous Administration Route, Intramuscular Administration Route and Intravenous Administration Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Brazil Historic Review for Growth Hormone Deficiency by Administration Route - Subcutaneous Administration Route, Intramuscular Administration Route and Intravenous Administration Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 298: Brazil 15-Year Perspective for Growth Hormone Deficiency by Administration Route - Percentage Breakdown of Value Sales for Subcutaneous Administration Route, Intramuscular Administration Route and Intravenous Administration Route for the Years 2015, 2025 & 2030
  • TABLE 299: Brazil Recent Past, Current & Future Analysis for Growth Hormone Deficiency by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Brazil Historic Review for Growth Hormone Deficiency by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 301: Brazil 15-Year Perspective for Growth Hormone Deficiency by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 302: Mexico Recent Past, Current & Future Analysis for Growth Hormone Deficiency by Treatment Type - Therapeutic, Recombinant Human Growth Hormone, Human Pituitary Gland Extracts and Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Mexico Historic Review for Growth Hormone Deficiency by Treatment Type - Therapeutic, Recombinant Human Growth Hormone, Human Pituitary Gland Extracts and Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 304: Mexico 15-Year Perspective for Growth Hormone Deficiency by Treatment Type - Percentage Breakdown of Value Sales for Therapeutic, Recombinant Human Growth Hormone, Human Pituitary Gland Extracts and Surgery for the Years 2015, 2025 & 2030
  • TABLE 305: Mexico Recent Past, Current & Future Analysis for Growth Hormone Deficiency by Disease Indication - Other Disease Indications, Pediatric Growth Hormone Deficiency, Idiopathic Short Stature, Small for Gestational Age, Turner Syndrome and Adult Growth Hormone Deficiency - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Mexico Historic Review for Growth Hormone Deficiency by Disease Indication - Other Disease Indications, Pediatric Growth Hormone Deficiency, Idiopathic Short Stature, Small for Gestational Age, Turner Syndrome and Adult Growth Hormone Deficiency Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 307: Mexico 15-Year Perspective for Growth Hormone Deficiency by Disease Indication - Percentage Breakdown of Value Sales for Other Disease Indications, Pediatric Growth Hormone Deficiency, Idiopathic Short Stature, Small for Gestational Age, Turner Syndrome and Adult Growth Hormone Deficiency for the Years 2015, 2025 & 2030
  • TABLE 308: Mexico Recent Past, Current & Future Analysis for Growth Hormone Deficiency by Administration Route - Subcutaneous Administration Route, Intramuscular Administration Route and Intravenous Administration Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 309: Mexico Historic Review for Growth Hormone Deficiency by Administration Route - Subcutaneous Administration Route, Intramuscular Administration Route and Intravenous Administration Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 310: Mexico 15-Year Perspective for Growth Hormone Deficiency by Administration Route - Percentage Breakdown of Value Sales for Subcutaneous Administration Route, Intramuscular Administration Route and Intravenous Administration Route for the Years 2015, 2025 & 2030
  • TABLE 311: Mexico Recent Past, Current & Future Analysis for Growth Hormone Deficiency by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 312: Mexico Historic Review for Growth Hormone Deficiency by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 313: Mexico 15-Year Perspective for Growth Hormone Deficiency by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 314: Rest of Latin America Recent Past, Current & Future Analysis for Growth Hormone Deficiency by Treatment Type - Therapeutic, Recombinant Human Growth Hormone, Human Pituitary Gland Extracts and Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 315: Rest of Latin America Historic Review for Growth Hormone Deficiency by Treatment Type - Therapeutic, Recombinant Human Growth Hormone, Human Pituitary Gland Extracts and Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 316: Rest of Latin America 15-Year Perspective for Growth Hormone Deficiency by Treatment Type - Percentage Breakdown of Value Sales for Therapeutic, Recombinant Human Growth Hormone, Human Pituitary Gland Extracts and Surgery for the Years 2015, 2025 & 2030
  • TABLE 317: Rest of Latin America Recent Past, Current & Future Analysis for Growth Hormone Deficiency by Disease Indication - Other Disease Indications, Pediatric Growth Hormone Deficiency, Idiopathic Short Stature, Small for Gestational Age, Turner Syndrome and Adult Growth Hormone Deficiency - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 318: Rest of Latin America Historic Review for Growth Hormone Deficiency by Disease Indication - Other Disease Indications, Pediatric Growth Hormone Deficiency, Idiopathic Short Stature, Small for Gestational Age, Turner Syndrome and Adult Growth Hormone Deficiency Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 319: Rest of Latin America 15-Year Perspective for Growth Hormone Deficiency by Disease Indication - Percentage Breakdown of Value Sales for Other Disease Indications, Pediatric Growth Hormone Deficiency, Idiopathic Short Stature, Small for Gestational Age, Turner Syndrome and Adult Growth Hormone Deficiency for the Years 2015, 2025 & 2030
  • TABLE 320: Rest of Latin America Recent Past, Current & Future Analysis for Growth Hormone Deficiency by Administration Route - Subcutaneous Administration Route, Intramuscular Administration Route and Intravenous Administration Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 321: Rest of Latin America Historic Review for Growth Hormone Deficiency by Administration Route - Subcutaneous Administration Route, Intramuscular Administration Route and Intravenous Administration Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 322: Rest of Latin America 15-Year Perspective for Growth Hormone Deficiency by Administration Route - Percentage Breakdown of Value Sales for Subcutaneous Administration Route, Intramuscular Administration Route and Intravenous Administration Route for the Years 2015, 2025 & 2030
  • TABLE 323: Rest of Latin America Recent Past, Current & Future Analysis for Growth Hormone Deficiency by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 324: Rest of Latin America Historic Review for Growth Hormone Deficiency by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 325: Rest of Latin America 15-Year Perspective for Growth Hormone Deficiency by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Growth Hormone Deficiency Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 326: Middle East Recent Past, Current & Future Analysis for Growth Hormone Deficiency by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 327: Middle East Historic Review for Growth Hormone Deficiency by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 328: Middle East 15-Year Perspective for Growth Hormone Deficiency by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 329: Middle East Recent Past, Current & Future Analysis for Growth Hormone Deficiency by Treatment Type - Therapeutic, Recombinant Human Growth Hormone, Human Pituitary Gland Extracts and Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 330: Middle East Historic Review for Growth Hormone Deficiency by Treatment Type - Therapeutic, Recombinant Human Growth Hormone, Human Pituitary Gland Extracts and Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 331: Middle East 15-Year Perspective for Growth Hormone Deficiency by Treatment Type - Percentage Breakdown of Value Sales for Therapeutic, Recombinant Human Growth Hormone, Human Pituitary Gland Extracts and Surgery for the Years 2015, 2025 & 2030
  • TABLE 332: Middle East Recent Past, Current & Future Analysis for Growth Hormone Deficiency by Disease Indication - Other Disease Indications, Pediatric Growth Hormone Deficiency, Idiopathic Short Stature, Small for Gestational Age, Turner Syndrome and Adult Growth Hormone Deficiency - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 333: Middle East Historic Review for Growth Hormone Deficiency by Disease Indication - Other Disease Indications, Pediatric Growth Hormone Deficiency, Idiopathic Short Stature, Small for Gestational Age, Turner Syndrome and Adult Growth Hormone Deficiency Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 334: Middle East 15-Year Perspective for Growth Hormone Deficiency by Disease Indication - Percentage Breakdown of Value Sales for Other Disease Indications, Pediatric Growth Hormone Deficiency, Idiopathic Short Stature, Small for Gestational Age, Turner Syndrome and Adult Growth Hormone Deficiency for the Years 2015, 2025 & 2030
  • TABLE 335: Middle East Recent Past, Current & Future Analysis for Growth Hormone Deficiency by Administration Route - Subcutaneous Administration Route, Intramuscular Administration Route and Intravenous Administration Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 336: Middle East Historic Review for Growth Hormone Deficiency by Administration Route - Subcutaneous Administration Route, Intramuscular Administration Route and Intravenous Administration Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 337: Middle East 15-Year Perspective for Growth Hormone Deficiency by Administration Route - Percentage Breakdown of Value Sales for Subcutaneous Administration Route, Intramuscular Administration Route and Intravenous Administration Route for the Years 2015, 2025 & 2030
  • TABLE 338: Middle East Recent Past, Current & Future Analysis for Growth Hormone Deficiency by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 339: Middle East Historic Review for Growth Hormone Deficiency by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 340: Middle East 15-Year Perspective for Growth Hormone Deficiency by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 341: Iran Recent Past, Current & Future Analysis for Growth Hormone Deficiency by Treatment Type - Therapeutic, Recombinant Human Growth Hormone, Human Pituitary Gland Extracts and Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 342: Iran Historic Review for Growth Hormone Deficiency by Treatment Type - Therapeutic, Recombinant Human Growth Hormone, Human Pituitary Gland Extracts and Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 343: Iran 15-Year Perspective for Growth Hormone Deficiency by Treatment Type - Percentage Breakdown of Value Sales for Therapeutic, Recombinant Human Growth Hormone, Human Pituitary Gland Extracts and Surgery for the Years 2015, 2025 & 2030
  • TABLE 344: Iran Recent Past, Current & Future Analysis for Growth Hormone Deficiency by Disease Indication - Other Disease Indications, Pediatric Growth Hormone Deficiency, Idiopathic Short Stature, Small for Gestational Age, Turner Syndrome and Adult Growth Hormone Deficiency - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 345: Iran Historic Review for Growth Hormone Deficiency by Disease Indication - Other Disease Indications, Pediatric Growth Hormone Deficiency, Idiopathic Short Stature, Small for Gestational Age, Turner Syndrome and Adult Growth Hormone Deficiency Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 346: Iran 15-Year Perspective for Growth Hormone Deficiency by Disease Indication - Percentage Breakdown of Value Sales for Other Disease Indications, Pediatric Growth Hormone Deficiency, Idiopathic Short Stature, Small for Gestational Age, Turner Syndrome and Adult Growth Hormone Deficiency for the Years 2015, 2025 & 2030
  • TABLE 347: Iran Recent Past, Current & Future Analysis for Growth Hormone Deficiency by Administration Route - Subcutaneous Administration Route, Intramuscular Administration Route and Intravenous Administration Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 348: Iran Historic Review for Growth Hormone Deficiency by Administration Route - Subcutaneous Administration Route, Intramuscular Administration Route and Intravenous Administration Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 349: Iran 15-Year Perspective for Growth Hormone Deficiency by Administration Route - Percentage Breakdown of Value Sales for Subcutaneous Administration Route, Intramuscular Administration Route and Intravenous Administration Route for the Years 2015, 2025 & 2030
  • TABLE 350: Iran Recent Past, Current & Future Analysis for Growth Hormone Deficiency by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 351: Iran Historic Review for Growth Hormone Deficiency by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 352: Iran 15-Year Perspective for Growth Hormone Deficiency by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 353: Israel Recent Past, Current & Future Analysis for Growth Hormone Deficiency by Treatment Type - Therapeutic, Recombinant Human Growth Hormone, Human Pituitary Gland Extracts and Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 354: Israel Historic Review for Growth Hormone Deficiency by Treatment Type - Therapeutic, Recombinant Human Growth Hormone, Human Pituitary Gland Extracts and Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 355: Israel 15-Year Perspective for Growth Hormone Deficiency by Treatment Type - Percentage Breakdown of Value Sales for Therapeutic, Recombinant Human Growth Hormone, Human Pituitary Gland Extracts and Surgery for the Years 2015, 2025 & 2030
  • TABLE 356: Israel Recent Past, Current & Future Analysis for Growth Hormone Deficiency by Disease Indication - Other Disease Indications, Pediatric Growth Hormone Deficiency, Idiopathic Short Stature, Small for Gestational Age, Turner Syndrome and Adult Growth Hormone Deficiency - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 357: Israel Historic Review for Growth Hormone Deficiency by Disease Indication - Other Disease Indications, Pediatric Growth Hormone Deficiency, Idiopathic Short Stature, Small for Gestational Age, Turner Syndrome and Adult Growth Hormone Deficiency Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 358: Israel 15-Year Perspective for Growth Hormone Deficiency by Disease Indication - Percentage Breakdown of Value Sales for Other Disease Indications, Pediatric Growth Hormone Deficiency, Idiopathic Short Stature, Small for Gestational Age, Turner Syndrome and Adult Growth Hormone Deficiency for the Years 2015, 2025 & 2030
  • TABLE 359: Israel Recent Past, Current & Future Analysis for Growth Hormone Deficiency by Administration Route - Subcutaneous Administration Route, Intramuscular Administration Route and Intravenous Administration Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 360: Israel Historic Review for Growth Hormone Deficiency by Administration Route - Subcutaneous Administration Route, Intramuscular Administration Route and Intravenous Administration Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 361: Israel 15-Year Perspective for Growth Hormone Deficiency by Administration Route - Percentage Breakdown of Value Sales for Subcutaneous Administration Route, Intramuscular Administration Route and Intravenous Administration Route for the Years 2015, 2025 & 2030
  • TABLE 362: Israel Recent Past, Current & Future Analysis for Growth Hormone Deficiency by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 363: Israel Historic Review for Growth Hormone Deficiency by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 364: Israel 15-Year Perspective for Growth Hormone Deficiency by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 365: Saudi Arabia Recent Past, Current & Future Analysis for Growth Hormone Deficiency by Treatment Type - Therapeutic, Recombinant Human Growth Hormone, Human Pituitary Gland Extracts and Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 366: Saudi Arabia Historic Review for Growth Hormone Deficiency by Treatment Type - Therapeutic, Recombinant Human Growth Hormone, Human Pituitary Gland Extracts and Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 367: Saudi Arabia 15-Year Perspective for Growth Hormone Deficiency by Treatment Type - Percentage Breakdown of Value Sales for Therapeutic, Recombinant Human Growth Hormone, Human Pituitary Gland Extracts and Surgery for the Years 2015, 2025 & 2030
  • TABLE 368: Saudi Arabia Recent Past, Current & Future Analysis for Growth Hormone Deficiency by Disease Indication - Other Disease Indications, Pediatric Growth Hormone Deficiency, Idiopathic Short Stature, Small for Gestational Age, Turner Syndrome and Adult Growth Hormone Deficiency - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 369: Saudi Arabia Historic Review for Growth Hormone Deficiency by Disease Indication - Other Disease Indications, Pediatric Growth Hormone Deficiency, Idiopathic Short Stature, Small for Gestational Age, Turner Syndrome and Adult Growth Hormone Deficiency Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 370: Saudi Arabia 15-Year Perspective for Growth Hormone Deficiency by Disease Indication - Percentage Breakdown of Value Sales for Other Disease Indications, Pediatric Growth Hormone Deficiency, Idiopathic Short Stature, Small for Gestational Age, Turner Syndrome and Adult Growth Hormone Deficiency for the Years 2015, 2025 & 2030
  • TABLE 371: Saudi Arabia Recent Past, Current & Future Analysis for Growth Hormone Deficiency by Administration Route - Subcutaneous Administration Route, Intramuscular Administration Route and Intravenous Administration Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 372: Saudi Arabia Historic Review for Growth Hormone Deficiency by Administration Route - Subcutaneous Administration Route, Intramuscular Administration Route and Intravenous Administration Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 373: Saudi Arabia 15-Year Perspective for Growth Hormone Deficiency by Administration Route - Percentage Breakdown of Value Sales for Subcutaneous Administration Route, Intramuscular Administration Route and Intravenous Administration Route for the Years 2015, 2025 & 2030
  • TABLE 374: Saudi Arabia Recent Past, Current & Future Analysis for Growth Hormone Deficiency by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 375: Saudi Arabia Historic Review for Growth Hormone Deficiency by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 376: Saudi Arabia 15-Year Perspective for Growth Hormone Deficiency by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 377: UAE Recent Past, Current & Future Analysis for Growth Hormone Deficiency by Treatment Type - Therapeutic, Recombinant Human Growth Hormone, Human Pituitary Gland Extracts and Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 378: UAE Historic Review for Growth Hormone Deficiency by Treatment Type - Therapeutic, Recombinant Human Growth Hormone, Human Pituitary Gland Extracts and Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 379: UAE 15-Year Perspective for Growth Hormone Deficiency by Treatment Type - Percentage Breakdown of Value Sales for Therapeutic, Recombinant Human Growth Hormone, Human Pituitary Gland Extracts and Surgery for the Years 2015, 2025 & 2030
  • TABLE 380: UAE Recent Past, Current & Future Analysis for Growth Hormone Deficiency by Disease Indication - Other Disease Indications, Pediatric Growth Hormone Deficiency, Idiopathic Short Stature, Small for Gestational Age, Turner Syndrome and Adult Growth Hormone Deficiency - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 381: UAE Historic Review for Growth Hormone Deficiency by Disease Indication - Other Disease Indications, Pediatric Growth Hormone Deficiency, Idiopathic Short Stature, Small for Gestational Age, Turner Syndrome and Adult Growth Hormone Deficiency Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 382: UAE 15-Year Perspective for Growth Hormone Deficiency by Disease Indication - Percentage Breakdown of Value Sales for Other Disease Indications, Pediatric Growth Hormone Deficiency, Idiopathic Short Stature, Small for Gestational Age, Turner Syndrome and Adult Growth Hormone Deficiency for the Years 2015, 2025 & 2030
  • TABLE 383: UAE Recent Past, Current & Future Analysis for Growth Hormone Deficiency by Administration Route - Subcutaneous Administration Route, Intramuscular Administration Route and Intravenous Administration Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 384: UAE Historic Review for Growth Hormone Deficiency by Administration Route - Subcutaneous Administration Route, Intramuscular Administration Route and Intravenous Administration Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 385: UAE 15-Year Perspective for Growth Hormone Deficiency by Administration Route - Percentage Breakdown of Value Sales for Subcutaneous Administration Route, Intramuscular Administration Route and Intravenous Administration Route for the Years 2015, 2025 & 2030
  • TABLE 386: UAE Recent Past, Current & Future Analysis for Growth Hormone Deficiency by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 387: UAE Historic Review for Growth Hormone Deficiency by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 388: UAE 15-Year Perspective for Growth Hormone Deficiency by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 389: Rest of Middle East Recent Past, Current & Future Analysis for Growth Hormone Deficiency by Treatment Type - Therapeutic, Recombinant Human Growth Hormone, Human Pituitary Gland Extracts and Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 390: Rest of Middle East Historic Review for Growth Hormone Deficiency by Treatment Type - Therapeutic, Recombinant Human Growth Hormone, Human Pituitary Gland Extracts and Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 391: Rest of Middle East 15-Year Perspective for Growth Hormone Deficiency by Treatment Type - Percentage Breakdown of Value Sales for Therapeutic, Recombinant Human Growth Hormone, Human Pituitary Gland Extracts and Surgery for the Years 2015, 2025 & 2030
  • TABLE 392: Rest of Middle East Recent Past, Current & Future Analysis for Growth Hormone Deficiency by Disease Indication - Other Disease Indications, Pediatric Growth Hormone Deficiency, Idiopathic Short Stature, Small for Gestational Age, Turner Syndrome and Adult Growth Hormone Deficiency - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 393: Rest of Middle East Historic Review for Growth Hormone Deficiency by Disease Indication - Other Disease Indications, Pediatric Growth Hormone Deficiency, Idiopathic Short Stature, Small for Gestational Age, Turner Syndrome and Adult Growth Hormone Deficiency Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 394: Rest of Middle East 15-Year Perspective for Growth Hormone Deficiency by Disease Indication - Percentage Breakdown of Value Sales for Other Disease Indications, Pediatric Growth Hormone Deficiency, Idiopathic Short Stature, Small for Gestational Age, Turner Syndrome and Adult Growth Hormone Deficiency for the Years 2015, 2025 & 2030
  • TABLE 395: Rest of Middle East Recent Past, Current & Future Analysis for Growth Hormone Deficiency by Administration Route - Subcutaneous Administration Route, Intramuscular Administration Route and Intravenous Administration Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 396: Rest of Middle East Historic Review for Growth Hormone Deficiency by Administration Route - Subcutaneous Administration Route, Intramuscular Administration Route and Intravenous Administration Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 397: Rest of Middle East 15-Year Perspective for Growth Hormone Deficiency by Administration Route - Percentage Breakdown of Value Sales for Subcutaneous Administration Route, Intramuscular Administration Route and Intravenous Administration Route for the Years 2015, 2025 & 2030
  • TABLE 398: Rest of Middle East Recent Past, Current & Future Analysis for Growth Hormone Deficiency by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 399: Rest of Middle East Historic Review for Growth Hormone Deficiency by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 400: Rest of Middle East 15-Year Perspective for Growth Hormone Deficiency by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
• AFRICA
  • Growth Hormone Deficiency Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 401: Africa Recent Past, Current & Future Analysis for Growth Hormone Deficiency by Treatment Type - Therapeutic, Recombinant Human Growth Hormone, Human Pituitary Gland Extracts and Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 402: Africa Historic Review for Growth Hormone Deficiency by Treatment Type - Therapeutic, Recombinant Human Growth Hormone, Human Pituitary Gland Extracts and Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 403: Africa 15-Year Perspective for Growth Hormone Deficiency by Treatment Type - Percentage Breakdown of Value Sales for Therapeutic, Recombinant Human Growth Hormone, Human Pituitary Gland Extracts and Surgery for the Years 2015, 2025 & 2030
  • TABLE 404: Africa Recent Past, Current & Future Analysis for Growth Hormone Deficiency by Disease Indication - Other Disease Indications, Pediatric Growth Hormone Deficiency, Idiopathic Short Stature, Small for Gestational Age, Turner Syndrome and Adult Growth Hormone Deficiency - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 405: Africa Historic Review for Growth Hormone Deficiency by Disease Indication - Other Disease Indications, Pediatric Growth Hormone Deficiency, Idiopathic Short Stature, Small for Gestational Age, Turner Syndrome and Adult Growth Hormone Deficiency Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 406: Africa 15-Year Perspective for Growth Hormone Deficiency by Disease Indication - Percentage Breakdown of Value Sales for Other Disease Indications, Pediatric Growth Hormone Deficiency, Idiopathic Short Stature, Small for Gestational Age, Turner Syndrome and Adult Growth Hormone Deficiency for the Years 2015, 2025 & 2030
  • TABLE 407: Africa Recent Past, Current & Future Analysis for Growth Hormone Deficiency by Administration Route - Subcutaneous Administration Route, Intramuscular Administration Route and Intravenous Administration Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 408: Africa Historic Review for Growth Hormone Deficiency by Administration Route - Subcutaneous Administration Route, Intramuscular Administration Route and Intravenous Administration Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 409: Africa 15-Year Perspective for Growth Hormone Deficiency by Administration Route - Percentage Breakdown of Value Sales for Subcutaneous Administration Route, Intramuscular Administration Route and Intravenous Administration Route for the Years 2015, 2025 & 2030
  • TABLE 410: Africa Recent Past, Current & Future Analysis for Growth Hormone Deficiency by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 411: Africa Historic Review for Growth Hormone Deficiency by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 412: Africa 15-Year Perspective for Growth Hormone Deficiency by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030

IV. COMPETITION